Knight Therapeutics Inc.
KHTRF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.06B
Close$
Share Statistics
| Market cap | $1.06 Billion |
|---|---|
| Enterprise Value | $1.00 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 0.05 |
| Outstanding Shares | 98,198,847 |
Return
| Return on Equity | 1.84% |
|---|---|
| Return on Assets | 1.41% |
| Return on Invested Capital | 2.01% |
Valuation & Multiples
| P/E Ratio | 73.62 |
|---|---|
| PEG | -100.34 |
| Price to Sales | 1.54 |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | 1.83 |
| Enterprise Value to EBIT | 58.09 |
| Enterprise Value to Net Income | 68 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$88.97 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$90.74 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Knight Therapeutics Inc.
830 employees
CEO: Samira Sakhia Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the developme...